Therefore, COPD-linked inflammation likely affects the clinical response to PD-1 blockade and NSCLC patients with a coexisting COPD may qualify for the treatment with immune checkpoint inhibitor20,23,24. Here, PDCD1 is linked to non-small cell lung carcinoma.